The efficacy of the Rességuier method in the treatment of fibromyalgia: a randomised controlled trial
Completed
- Conditions
- FibromyalgiaMusculoskeletal DiseasesOther soft tissue disorders, not elsewhere classified
- Registration Number
- ISRCTN62054712
- Lead Sponsor
- niversity of Florence (Italy)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
1. Diagnosis of fibromyalgia according to the American College of Rheumatology (ACR) criteria
2. No age limits
Exclusion Criteria
Does not meet the inclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Reduction of pain (Numerical Rating Scale [NRS]: 0 - 10)<br>2. Improvement of disability and quality of life, assessed by the 36-item Short Form (SF-36) Health Survey and Fibromyalgia Impact Questionnaire (FIQ)
- Secondary Outcome Measures
Name Time Method 1. Quality of movement (NRS: 0 - 10)<br>2. Ability to relax mind and body (NRS: 0 - 10)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the Rességuier method's impact on fibromyalgia central sensitization?
How does the Rességuier rehabilitation method compare to duloxetine and milnacipran in fibromyalgia pain reduction?
Which biomarkers correlate with improved outcomes in fibromyalgia patients undergoing Rességuier therapy?
What adverse events are reported in the University of Florence Rességuier method fibromyalgia trial (ISRCTN62054712)?
Are there combination therapies involving the Rességuier method for fibromyalgia, such as SNRI or NSAID integration?